100 results
6-K
EX-99.2
GLPG
Galapagos NV
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
milestones, opt-in, royalty or other payments, statements regarding our R&D plans, strategy, and outlook, including progress on our oncology … modalities, and their potential competitive position with respect to other treatment alternatives, statements regarding the global R&D collaboration
6-K
EX-99.15
GLPG
Galapagos NV
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
diseases with high unmet needs. Our R&D objectives are to develop best-in-class therapeutic options. Our capabilities comprise multiple drug modalities … Committee roles was completed between late 2022 and early 2023 in light of our strategic transformation and revised R&D strategy focused on immunology
6-K
EX-99.5
GLPG
Galapagos NV
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
and R&D support measures.
Because the company participates extensively in research and development activities, the company also benefits from multiple … subsidies and R&D support measures from certain government agencies. These subsidies and R&D support measures are generally used to partially reimburse
6-K
EX-99.1
GLPG
Galapagos NV
23 Feb 24
Galapagos announces full year 2023 results and outlook for 2024
6:41am
oncology R&D approach. The investment aligns with our innovation acceleration strategy to bring transformational medicines to patients around the world … and Gilead have been assigned to Alfasigma. The transaction was successfully completed on 31 January 2024. Freed-up resources will be reinvested in R&D growth
6-K
EX-99.1
gt7 s2w8vumgjjybu
6 Feb 24
Galapagos completes transaction to transfer Jyseleca® business to Alfasigma
6:00am
6-K
EX-99.1
999lgqfl9b3huc
4 Jan 24
Galapagos signs agreement to transfer Jyseleca® business to Alfasigma
4:05pm
6-K
EX-99.1
syfdx3
3 Nov 23
Galapagos reports third quarter 2023 results and releases new encouraging data from CAR-T studies for presentation at ASH 2023
8:26am
6-K
EX-99.1
t9weq a9ph
2 Nov 23
Galapagos concludes strategic evaluation and signs letter of intent to transfer Jyseleca® business to Alfasigma
7:15am
6-K
EX-99.1
3p88bfaewky80xuxb3i4
30 Aug 23
Galapagos announces start of Phase 2 study with selective TYK2 inhibitor, GLPG3667, in patients with active systemic lupus erythematosus
6:31am
6-K
EX-99.2
q2vc8w s5c0h
4 Aug 23
Galapagos announces first half-year 2023 financial results
4:05pm
6-K
EX-99.1
qo8taxwj 6ybtoudwjk
4 Aug 23
Galapagos announces first half-year 2023 financial results
4:05pm
6-K
EX-99.1
m712s90h1lp1
15 Jun 23
Galapagos appoints Thad Huston as Chief Financial Officer and Chief Operating Officer
5:03pm
6-K
EX-99.1
5dutzk qa
13 Jun 23
Galapagos appoints Dr. Susanne Schaffert as non-executive independent Director to its Board
7:53am
6-K
EX-99.1
s8h4p6f5drwuew
12 Jun 23
Current report (foreign)
7:32am
6-K
EX-99.1
rt1fybm rf5iy4
9 May 23
Galapagos creates new subscription right plans
5:02pm
6-K
EX-99.1
je9fcoiic73y9jrv
5 May 23
Galapagos announces first quarter 2023 financial results
4:05pm
6-K
EX-99.1
bne66soj yoz6
2 May 23
Galapagos announces departure of Bart Filius, Chief Operating Officer and Chief Financial Officer
4:49pm
6-K
EX-99.1
j4uqrdz
2 May 23
Current report (foreign)
4:15pm
6-K
EX-99.1
2105usvvsn063
26 Apr 23
Galapagos’ shareholders approve all resolutions proposed by the Board of Directors at the annual shareholders’ meeting
8:23am